Maternal schizophrenia and pregnancy outcome: Does the use of antipsychotics make a difference?
Introduction
The effect of antipsychotics on pregnant women has drawn much attention during the past few years. In terms of pregnancy outcome for women with schizophrenia however, the safety of antipsychotics remains unclear. Pregnant women with schizophrenia who discontinue antipsychotics are more likely to experience relapse. This could put them and their babies at greater risk, outweighing risks associated with antipsychotics use (Newport et al., 2007). Therefore, treating expectant mothers with schizophrenia poses a challenge for patients, their families, and doctors, since the most common onset of schizophrenia is during childbearing ages (Miller, 1997).
Previous studies have attempted to document the impact of antipsychotics on pregnancy outcome, but have yielded inconsistent findings. A study by Newham et al. (2008) reported that in utero exposure to atypical antipsychotics may increase infant birth weight and incidences of babies large for gestational age (LGA). A study by Reis and Kallen (2008) found that the maternal use of antipsychotics was not associated with preterm births, low birth weight (LBW), or SGA. McKenna et al. (2005) concluded that women exposed to atypical antipsychotics had significantly higher rates of low birth weight (LBW) infants than those in the comparison group (10% vs. 2%). However, the above studies not only look at different sets of outcome, all analyses fail to take the disorder itself into consideration. A plethora of studies have consistently demonstrated the relationship between schizophrenia and adverse pregnancy outcome. Therefore, studies of the effect of antipsychotics on pregnancy outcome based on samples that mixed patients with diverse types of mental disorders or other chronic disorders may confound the findings.
Using a nationwide population-based dataset from Taiwan, the objective of this study was to compare the risk of adverse pregnancy outcome including preterm birth, LBW, LGA, and SGA among mothers with schizophrenia receiving typical, atypical, and no antipsychotics during pregnancy and comparison subjects after adjusting for the characteristics of mother, father, and infant. We hypothesized that the risk of adverse birth outcome increased among women with schizophrenia, as compared to those without a psychiatric illness. The maternal use of physician-approved antipsychotic medication during pregnancy would possess minimal excess risk to the pregnancy outcome. These findings may help clinicians understand the possible impact of antipsychotics on pregnancy outcome and indicate a better treatment choice for optimal control of schizophrenic symptoms during pregnancy.
Section snippets
Database
For this study, we linked two nationwide population-based datasets. The first dataset was sourced from the Taiwan National Health Insurance Research Dataset (NHIRD), covering the years 1996 to 2003. Taiwan inaugurated its National Health Insurance (NHI) program in 1995 as a means of financing healthcare for all Taiwanese citizens. The NHI has the following characteristics: universal health insurance coverage, a single-payer system with the government as the sole insurer and payer, comprehensive
Results
A total of 696 mothers with schizophrenia during the study period were identified. In 242 pregnancies, mothers received antipsychotics for treatment of schizophrenia. The mean duration of antipsychotics use was 164 days (standard deviation = 113 days). In 194 of these pregnancies, the women received typical antipsychotics. The distribution of antipsychotics used during pregnancy is listed in Table 1. Table 2 shows the study and comparison cohort distributions of the infant, mother, and father
Discussion
In this nationwide, population-based retrospective study, women with schizophrenia, regardless of whether they had received antipsychotics during pregnancy, had an increased risk of delivering babies with LBW and SGA than the comparison cohort. As shown by an earlier meta-analytic study, women with schizophrenia were at higher risk for obstetric complications, including LBW and poor neonatal conditions, than the general population (Sacker et al., 1996). Several recent studies have provided more
Role of funding source
None.
Contributors
Authors Herng-Ching Lin and I-Ju Chen designed the study and wrote the draft. Authors Dr. Yi-Hua Chen, Hsin-Chien Lee, I-Ju Chen and Fang-Jen Wu managed the literature searches and analyses. Authors Herng-Ching Lin, Yi-Hua Chen and Hsin-Chien Lee undertook the statistical analysis. All authors contributed to and have approved the final manuscript.
Conflict of interest
None.
Acknowledgements
This study is based in part on the data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health and managed by the National Health Research Institutes, Taiwan. The interpretations and conclusions contained herein do not represent those of the Bureau of National Health Insurance, Department of Health, or the National Health Research Institutes.
References (16)
- et al.
Small left colon syndrome associated with maternal ingestion of psychotropic drugs
J. Pediatr.
(1980) Clinical management guidelines for obstetrician–gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation
Obstet. Gynecol.
(2008)Clinical utilization of atypical antipsychotics in pregnancy and lactation
Ann. Pharmacother.
(2004)Pregnancy and psychiatric drugs
Hosp. Community Psychiatr.
(1985)- et al.
Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders
Am. J. Psychiatry
(2005) - et al.
Exploring boundaries of schizophrenia: a comparison of ICD-10 with other diagnostic systems in first-admitted patients
World Psychiatry
(2002) Psychotropic medication in pregnancy
Adv. Psychiatr. Treat.
(2004)The contribution of low birth weight to infant mortality and childhood morbidity
N. Engl. J. Med.
(1985)
Cited by (91)
Adverse perinatal pregnancy outcomes in women with schizophrenia: A systematic review and meta-analysis
2023, Schizophrenia ResearchAntipsychotic Use in Early Pregnancy and the Risk of Maternal and Neonatal Complications
2022, Mayo Clinic ProceedingsTreatment-resistant depression in pregnancy, the postpartum period, and transition to menopause
2022, Managing Treatment-Resistant Depression: Road to Novel TherapeuticsAntipsychotic drug use in pregnancy: A multinational study from ten countries
2020, Schizophrenia ResearchCitation Excerpt :Discontinuation of antipsychotic treatment during pregnancy may increase the risk of recurrence of mental disorders including bipolar disorder (Viguera et al., 2007) and psychosis (Tosato et al., 2017). On the other hand, potential risks associated with antipsychotic use during pregnancy include metabolic disturbances, abnormal fetal growth (Boden et al., 2012b), preterm birth (Lin et al., 2010), as well as congenital anomalies (Huybrechts et al., 2016). However, findings to date are not consistent and some increased risks for adverse outcomes may be illness-rather than drug-related (Boden et al., 2012a).
Relationship Between Depression and/or Anxiety and Hospital Readmission Among Women After Childbirth
2019, JOGNN - Journal of Obstetric, Gynecologic, and Neonatal NursingPerinatal anxiety: approach to diagnosis and management in the obstetric setting
2018, American Journal of Obstetrics and GynecologyCitation Excerpt :Quetiapine (Seroquel) at low doses has demonstrated efficacy for GAD in nonpregnant populations and commonly is used by reproductive psychiatrists for symptom management of severe perinatal anxiety in women who should avoid benzodiazepines because of intolerance or misuse.160 Reproductive safety data are limited, although largely reassuring,140,161-179 and obstetric providers who consider the use of quetiapine would ideally do so with psychiatric input. Despite their limitations, short-term use of adjunctive medications is often critical to prevent worsening of maternal illness and should be part of every obstetric provider’s toolbox.